📊 RNXT Key Takeaways
Is RenovoRx, Inc. (RNXT) a Good Investment?
RenovoRx shows exceptional early-stage revenue growth (+2511% YoY) and strong gross margins (70.9%), indicating successful initial commercialization of its pharmaceutical product. However, the company faces critical near-term challenges: it is burning ~$11M annually with only ~$7M in cash on hand, providing less than one year of runway, combined with operating losses of $12.5M and net losses of $11.2M with no clear path to profitability.
Revenue has inflected from a very low base with strong gross margins, but operations remain deeply unprofitable with extreme negative operating and net margins. Cash burn materially exceeds scale of the business, implying likely near-term financing needs; without clear operating leverage and sustained revenue traction, fundamentals are unfavorable.
Why Buy RenovoRx, Inc. Stock? RNXT Key Strengths
- Exceptional revenue growth of 2511.6% YoY demonstrates strong market traction and commercialization success
- Healthy gross margin of 70.9% indicates the product economics and unit business model are fundamentally sound
- Strong liquidity position with 4.02x current ratio and minimal debt (0.00x debt/to-equity), reducing financial distress risk
- High gross margin (70.9%) indicating potential unit economics if scaled
- Solid liquidity (current ratio 4.0x) with zero long-term debt
- Minimal capex supports an asset-light model
RNXT Stock Risks: RenovoRx, Inc. Investment Risks
- Critical cash runway: $7M in cash with $11M annual burn rate provides less than 9 months of operations; company will need dilutive financing or must achieve dramatic revenue acceleration
- Deeply negative net income (-$11.2M) and operating income (-$12.5M) indicate operations far from breakeven; no clear inflection point to profitability
- Early-stage pharmaceutical company with execution risk; continued revenue growth is not guaranteed and requires successful market adoption
- Severe operating losses and negative ROE/ROA point to unsustainable economics
- High cash burn relative to $7.02M cash raises financing/dilution risk
- Execution/regulatory uncertainty typical in pharma could hinder commercialization
Key Metrics to Watch
- Quarterly revenue run-rate and sustainability of growth beyond initial commercialization phase
- Monthly cash burn rate and cash runway; any additional financing announcements
- Gross margin stability and operating expense control as company scales
- Operating cash flow (quarterly burn rate)
- Operating margin (progress toward breakeven)
RenovoRx, Inc. (RNXT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.02x current ratio provides a solid financial cushion.
RNXT Profit Margin, ROE & Profitability Analysis
RNXT vs Healthcare Sector: How RenovoRx, Inc. Compares
How RenovoRx, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RenovoRx, Inc. Stock Overvalued? RNXT Valuation Analysis 2026
Based on fundamental analysis, RenovoRx, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RenovoRx, Inc. Balance Sheet: RNXT Debt, Cash & Liquidity
RNXT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: RenovoRx, Inc.'s revenue has grown significantly by 2,512% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.40 indicates the company is currently unprofitable.
RNXT Revenue Growth, EPS Growth & YoY Performance
RNXT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $266.0K | -$1.1M | $-0.08 |
| Q2 2025 | $422.0K | -$1.1M | $-0.08 |
| Q1 2025 | $197.0K | -$1.1M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RenovoRx, Inc. Dividends, Buybacks & Capital Allocation
RNXT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for RenovoRx, Inc. (CIK: 0001574094)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RNXT
What is the AI rating for RNXT?
RenovoRx, Inc. (RNXT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RNXT's key strengths?
Claude: Exceptional revenue growth of 2511.6% YoY demonstrates strong market traction and commercialization success. Healthy gross margin of 70.9% indicates the product economics and unit business model are fundamentally sound. ChatGPT: High gross margin (70.9%) indicating potential unit economics if scaled. Solid liquidity (current ratio 4.0x) with zero long-term debt.
What are the risks of investing in RNXT?
Claude: Critical cash runway: $7M in cash with $11M annual burn rate provides less than 9 months of operations; company will need dilutive financing or must achieve dramatic revenue acceleration. Deeply negative net income (-$11.2M) and operating income (-$12.5M) indicate operations far from breakeven; no clear inflection point to profitability. ChatGPT: Severe operating losses and negative ROE/ROA point to unsustainable economics. High cash burn relative to $7.02M cash raises financing/dilution risk.
What is RNXT's revenue and growth?
RenovoRx, Inc. reported revenue of $1.1M.
Does RNXT pay dividends?
RenovoRx, Inc. does not currently pay dividends.
Where can I find RNXT SEC filings?
Official SEC filings for RenovoRx, Inc. (CIK: 0001574094) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RNXT's EPS?
RenovoRx, Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RNXT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, RenovoRx, Inc. has a SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RNXT stock overvalued or undervalued?
Valuation metrics for RNXT: ROE of -206.0% (sector avg: 15%), net margin of -994.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RNXT stock in 2026?
Our dual AI analysis gives RenovoRx, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RNXT's free cash flow?
RenovoRx, Inc.'s operating cash flow is $-11.0M, with capital expenditures of $2.0K. FCF margin is -977.3%.
How does RNXT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -994.5% (avg: 12%), ROE -206.0% (avg: 15%), current ratio 4.02 (avg: 2).